首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting
【24h】

Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting

机译:超声分子成像作为潜在的无侵入性诊断,以通过CSF-1R靶向检测肝癌的余量

获取原文
获取外文期刊封面目录资料

摘要

Though radiofrequency ablation (RFA) is considered to be an effective treatment for hepatocellular carcinoma (HCC), but more than 30% of patients may suffer insufficient RFA (IRFA), which can promote more aggressive of the residual tumor. One possible method to counter this is to accurately identify the margin of the HCC. CSF-1R has been found to be restrictively expressed by tumor associated macrophages (TAMs) and monocytes which more prefer to locate at the boundary of HCC. Using biotinylation method, we developed a CSF-1R-conjugated nanobubble CSF-1R (NBCSF-1R) using a thin-film hydration method for margin detection of HCC. CSF-1R expression was higher in macrophages than in HCC cell lines. Furthermore, immunofluorescence showed that CSF-1R were largely located in the margin of xenograft tumor and IFRA models. In vitro, NBCSF-1R was stable and provided a clear ultrasound image even after being stored for 6 months. In co-culture, NBCSF-1R adhered to macrophages significantly better than HCC cells (p0.05). In in vivo contrast-enhanced ultrasound imaging, the washout half-time of the NBCSF-1R was significantly greater than that of NBCTRL and Sonovue? (p0.05). The signal intensity of the tumor periphery was higher than the tumor center or non-tumor region after NBCSF-1R injection. Taken together, NBCSF-1R may potentially be used as a non-invasive diagnostic modality in the margin detection of HCC, thereby improving the efficiency of RFA. This platform may also serve as a complement method to detect residual HCC after RFA; and may also be used for targeted delivery of therapeutic drugs or genes.
机译:虽然射频消融(RFA)被认为是对肝细胞癌(HCC)的有效治疗,但超过30%的患者可能患有不足的RFA(IRFA),这可以促进更容易的残留肿瘤。要计数器的一种可能方法是准确地识别HCC的边缘。已发现CSF-1R通过肿瘤相关的巨噬细胞(TAMS)和单核细胞来限制性地表达,所述单核细胞更倾向于定位在HCC的边界处。使用生物素化方法,我们使用薄膜水合方法开发了CSF-1R缀合的纳米柔臼CSF-1R(NBCSF-1R),用于HCC的边缘检测。 CSF-1R表达在巨噬细胞中高于HCC细胞系。此外,免疫荧光表明,CSF-1R在很大程度上位于异种移植肿瘤和IFRA模型的边缘。在体外,即使在储存6个月后,NBCSF-1R也稳定并提供清晰的超声图像。在共培养中,NBCSF-1R粘附在巨噬细胞上明显优于HCC细胞(P <0.05)。在体内对比度增强的超声成像中,NBCSF-1R的冲洗半时间明显大于NBCTRL和Sonovue的半时间? (P <0.05)。 NBCSF-1R注射后,肿瘤周边的信号强度高于肿瘤中心或非肿瘤区。一起携带NBCSF-1R可能用作HCC的边缘检测中的非侵入性诊断方式,从而提高RFA的效率。该平台还可以作为RFA之后检测残留的HCC的补充方法;并且也可用于靶向递送治疗药物或基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号